Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis.

Qian ZhuLu WangXiaoxiao HuYingzhi ZhangTianquan HuangTaiyu HeZhiwei ChenGaoli ZhangMingli PengMin ChenDachuan CaiXiaofeng Shi Hong Ren

Published in: Journal of clinical and translational hepatology (2023)

A booster dose elicited a robust and durable humoral response to the wild-type strain in cirrhotic patients but not the Omicron subvariants. Repeated vaccination of inactivated SARS-CoV-2 vaccine may not benefit cirrhotic patients in neutralization against newly circulating strains.

Keyphrases

immune response
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
wild type
respiratory syndrome coronavirus
toll like receptor